Related Experiment Video

Updated: Mar 9, 2026

Quantifying the Effects of Antimicrobials on In vitro Biofilm Architecture using COMSTAT Software
06:18

Quantifying the Effects of Antimicrobials on In vitro Biofilm Architecture using COMSTAT Software

Published on: December 14, 2020

4.4K

Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application

Juwon Yim1, Leah M Molloy2, Jason G Newland3,4

  • 1St. John Hospital and Medical Center, Detroit, MI, USA. ft0702@wayne.edu.

Infectious Diseases and Therapy
|January 1, 2017
PubMed

Insights

Ceftaroline is a new cephalosporin effective for pediatric bacterial infections, including those resistant to other antibiotics. Further research is needed on its use in very young infants and those with complex conditions.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Pediatrics

Background:

  • Ceftaroline is a novel cephalosporin approved for pediatric bacterial infections.
  • It shows efficacy against resistant Gram-positive and Gram-negative bacteria, including MRSA.
  • It is indicated for acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia (CABP).

Purpose of the Study:

  • To review the microbiological and pharmacokinetic profile of ceftaroline.
  • To discuss the clinical evidence for its use in pediatric patients.
  • To propose its place in pediatric therapy.

Main Methods:

  • Literature review of microbiological data.
  • Analysis of pharmacokinetic studies in pediatric populations.
  • Evaluation of clinical trial data for efficacy and tolerability.

Main Results:

  • Ceftaroline demonstrates excellent in vitro activity against resistant pathogens.
  • Proven efficacy and favorable tolerability in pediatric patients for specific infections.
  • Potential therapeutic option for challenging infections and resistant bacteria.

Conclusions:

  • Ceftaroline is a valuable option for pediatric bacterial infections, especially those involving resistant organisms.
  • Further investigation is required for neonates and infants <2 months.
  • Pharmacokinetic data in children with chronic or invasive infections need more study.

Keywords:
Antibiotic resistanceCeftaroline fosamilChildrenMethicillin-resistant Staphylococcus aureusStreptococcus pneumoniae

More Related Videos

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K
Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.9K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
343
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
306
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
595
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
407
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
637